Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study - A multivariate analysis

Heart and Vascular Research Center, Hamann 3rd Floor, MetroHealth Campus, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, Ohio 44109-1998, USA.
Journal of the American College of Cardiology (Impact Factor: 16.5). 09/2004; 44(6):1276-82. DOI: 10.1016/j.jacc.2004.06.052
Source: PubMed


This study examined the risk of proarrhythmic events in patients receiving antiarrhythmic drugs for treatment of atrial fibrillation (AF) according to present-day safety guidelines.
Advances in understanding the proarrhythmic risk of antiarrhythmic drugs has led to development of safety guidelines for these agents. Such guidelines were used in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
This study was an analysis of the risk of arrhythmic events (arrhythmic death, resuscitated cardiac arrest, sustained ventricular tachycardia (VT), and torsade de pointes VT) in the antiarrhythmic drug arm of the AFFIRM study. Each time an antiarrhythmic drug was begun, it was counted as an exposure to that drug and the risk of an arrhythmic event was calculated.
A total of 2,033 patients received 3,030 exposures to antiarrhythmic drugs. Ninety-six arrhythmic events occurred by six years. Patients with a left ventricular ejection fraction <40% had more arrhythmic events. Twelve documented cases of torsade de pointes VT were noted. The incidence of torsade de pointes was 0.6% at five years (95% confidence interval 0.32 to 1.07).
The overall risk of adverse arrhythmic events upon exposure to antiarrhythmic drugs in the AFFIRM study was reasonably low. Strict criteria for the safe use of antiarrhythmic drugs were successful in minimizing proarrhythmic events.

Download full-text


Available from: Ted Wang, Jan 16, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Amiodarone,(AM) is a potent antidysrhythmic agent which can cause potentially life- threatening pulmonary fibrosis, and N-desethylamiodarone (DEA) is a metabolite of AM that may contribute to the toxicity of AM in vivo. Recent evidence has implicated the involvement,of the renin-angiotensin system (RAS) in the initiation and progression of amiodarone-induced pulmonary,toxicity. In cultured HPL1A human peripheral lung epithelial cells, we found AM to be converted to DEA minimally (< 2%) after 24 h of incubation, indicating that the HPL1A cell culture model can be used to study the effects of AM and DEA independently. Apoptotic cell death was
    Preview · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACTThe Autoregressive Dimensional Index (ARDI) was measured in a subset of R-R recordings corresponding to 257 patients from the Cardiac Arrhythmia Suppression Trial (CAST)-study, both before, and during treatment with the anti-arrhythmic drug Encainide (E). Encainide induced an average ARDI increase of 47% (P<0.001, paired t-test). <>A similar analysis with 127 patients treated with Flecainide (F) did not reveal statistical differences related to treatment. Since ARDI is negatively correlated to the Fractal Dimension (FD) of HRV data (Hernandez et al, Electron J Biomed 2004;1:4-15) we conclude that E exerts a reduction in FD among these patients. Since changes suggesting FD reduction are predictive of health worsening and sudden death, our results may provide an explanation for the reported increase in mortality induced by E among CAST patients. The lack of effect from F may be in agreement with recent reports suggesting that this drug does not increase the risk of sudden death.RESUMENEl Índice Dimensional Autorregresivo (Autoregressive Dimensional Index ARDI) fue evaluado sobre un subconjunto de registros de intervalos R-R correspondientes a 257 pacientes incluidos en el estudio "CAST", un conocido ensayo de supresión de arritmia en pacientes que sufrieron infarto agudo del miocardio. Los registros fueron obtenidos tanto antes como durante el tratamiento con el medicamento antiarrítmico Encainida (E). La Encainida inducía un incremento en el valor de ARDI de aproximadamente un 47% (P<0.001, prueba de la "t" pareada).Un análisis similar realizado con 127 pacientes tratados con Flecainida (F) no mostró ningún cambio significativa asociada al tratamiento. Por cuanto ARDI se correlaciona negativamente con la Dimensión Fractal (FD) de los datos de variabilidad de la frecuencia cardiaca (Hernández et al, Electrón J Biomed 2004;1:4-15), concluimos que E ejerce una acción reductora de la FD en ese grupo de pacientes. Por cuanto la reducción de la FD predice acerca del empeoramiento de la salud y de muerte súbita, nuestros resultados pudieran brindar una explicación al incremento de la mortalidad asociada a E entre los pacientes participantes del estudio CAST. La ausencia de efecto por parte de F puede concordar con reportes recientes que sugieren que este medicamento no aumenta el riesgo de muerte súbita.
    Full-text · Article · Jan 2005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Arrhythmias and cardiac electrophysiology are some of the fastest developing fields in cardiology. New data from the AFFIRM and RACE trials, which compared atrial fibrillation management with rate control or rhythm control strategies, have been published during the last year. New antiarrhythmic drugs, such as azimilide or drodenarone are being evaluated also in other trials. At the same time, the results of the SPORTIF III trial have been published and showed similar tromboembolic risk reduction and less haemorrhagic risk with ximelagatran than with classical anticoagulants in patients with non-valvular atrial fibrillation. Research in the field of atrial fibrillation ablation remains highly active and several important contributions improving the technique or the knowledge about the mechanism of this arrhythmia have been published during the last year. There is continuous interest on new tools for ablation, such as new non-fluoroscopic navigation systems or remote magnetic navigation. Finally, sudden death primary prevention by defibrillator implantation in patients with ventricular dysfunction and non sustained spontaneous ventricular arrhythmias is at present the field with greatest interest about these devices. This has been shown by the publication and presentation of the results of the COMPANION, DEFINITE, SCD-HeFT, and DINAMIT trials.
    No preview · Article · Dec 2005 · Revista Española de Cardiología Suplementos
Show more